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Abstract
Community-acquired pneumonia (CAP) remains an important cause of morbidity and mortality. The implementation of CAP guidelines 
can decrease patient mortality and limit antibiotic resistance. The South African Thoracic Society (SATS) has revised its guidelines for 
the management of CAP in adults. This article reviews the management of CAP and explores the rationale for the recommendations 
regarding point of care and antibiotic therapy.
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Introduction
Pneumonia is the result of infection and inflammation of the lung 
parenchyma distal to the terminal bronchioles. CAP specifically refers 
to pneumonia acquired within the general community. CAP remains 
a common and potentially fatal infectious disease despite advances 
in therapy. CAP is the fifth-largest killer in South Africa, accounting for 
3.9% of all deaths in 2000.1 A recent South African study reported a 
mortality of 20% for patients hospitalised with CAP.2 The vast majority 
of patients with CAP can be safely managed as outpatients. In the 
United States of America only 20% of patients are hospitalised with 2% 
requiring management in an intensive care unit.3
A new group of pneumonia patients has been recognised – health 
care-associated pneumonia (HCAP). These patients are either resident 
in long-term care facilities or have frequent outpatient exposure to 
healthcare services. The bacteriology and management of patients 
with HCAP have more in common with nosocomial pneumonia and are 
a separate entity from CAP. Separate guidelines have been developed 
for the management of HCAP.4
Aetiology of community-acquired pneumonia
Several host defences need to be overcome in order for a pathogen 
to enter the host’s alveoli and establish an infection. While recognised 
risk factors for pneumonia such as cardio-respiratory disease, immune 
compromise and smoking may be present, no obvious predisposing 
cause is apparent in the majority of cases of CAP. Although a large 
number of organisms cause CAP, only a few organisms are associated 
with the majority of cases.5 This allows for empiric antibiotic selection 
without the need for extensive investigation into the causative agent 
in an individual patient. Even with extensive investigation a causative 
agent is not identified in 98% of outpatients and 40–60% of inpatients.6
Most studies on the cause of CAP have been conducted in 
hospitalised patients, and although the exact proportions of each 
organism may vary, the relative frequency remains fairly constant 
between countries. A review of published reports from North America 
found the following organisms responsible for CAP in hospitalised 
patients: Streptococcus pneumoniae (20–60%), Haemophilus 
influenzae (3–10%), Mycoplasma pneumoniae (1–6%), Chlamydia 
pneumoniae (4%), Legionella sp (2–8%), viruses (2%), aspiration 
(6–10%), Staphylococcus aureus (3%), Gram-negative bacilli 
(3–5%) and other identified organisms (10–20%).5 Since this review 
it has been recognised that a significant percentage of CAP may be  
polymicrobial.7
In the majority of studies S pneumoniae is the dominant organism 
across the spectrum of severity of CAP. The frequencies of the other 
pathogens vary in a predictable manner depending on age, co-
morbidity and severity. M pneumoniae has an increased frequency in 
mild CAP while Legionella sp, S aureus and Gram-negative organisms 
such as Klebsiella pneumoniae show an increased frequency in 
severe CAP.6 H influenzae is more common in patients with chronic 
obstructive airways disease (COPD) and is the second most common 
cause of CAP in patients with HIV infection. In a recent local study S. 
pneumoniae was identified in 50% of isolates. It should be noted that 
atypical organisms were identified in 21% of this group of hospitalised 
patients.2 The exact incidence of atypical pathogens as a cause of CAP 
in South Africa is uncertain, but it displays a cyclic variation over time 
and may be associated with outbreaks of CAP.8
Studies trying to determine the organisms responsible for mild CAP 
in persons treated as outpatients have been less congruent and 
demonstrate greater geographical variability. Viral pathogens, in 
particularly Influenza A, may play a greater role in this group of patients 
with 10–50% of cases being viral. The most frequent bacteria identified 
in these outpatient studies were H influenza, M pneumoniae and S 
pneumoniae.9
The high incidence of viruses in mild outpatient CAP makes this an 
attractive group to target for decreased antibiotic administration. 
Attempts have been made to identify patients with a viral pneumonia 
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who do not require antibiotic therapy.10 Clinical scores proposed to 
differentiate between viral and bacterial CAP are neither sensitive 
nor specific enough to use in clinical practice. There is a possibility 
that serum procalcitonin levels may be able to discriminate between 
those requiring and those not requiring an antibiotic; however, this 
is impractical on an outpatient basis and requires further investigation.11
Diagnosis and investigation of CAP  
A patient should be suspected of having pneumonia when presenting 
with an acute cough and one of the following: dyspnoea, tachypnoea, 
fever lasting more than four days or new focal chest signs. Elderly 
patients may present atypically with confusion or abdominal pain and 
few respiratory symptoms, thus a high index of suspicion is necessary 
in this group. The diagnosis of CAP should be confirmed with a chest 
radiograph.6
A chest radiograph is recommended for all patients with suspected 
pneumonia as history and examination alone have low sensitivity 
(47–69%) and specificity (50–75%).12 The chest radiograph not 
only confirms the diagnosis but also identifies features of severity, 
complications and any underlying pulmonary pathology. The chest 
radiograph may be normal in early disease.  
No additional investigations are required in previously healthy patients 
considered to have mild pneumonia; however, counselling and testing 
for HIV should be offered. 
Sputum Gram stain and culture should be reserved for patients with 
co-morbid disease and severe pneumonia. Only specimens with a 
Bartlett score of +2 (> 25 neutrophils and < 10 epithelial cells per low 
power field) are representative of the lower respiratory tract. A limitation 
of sputum is that certain organisms can cause both colonisation and 
disease. Sputum should be submitted for acid-fast bacilli (auramine 
or Ziehl-Neelsen stain) if tuberculous infection is suspected. Induced 
sputum should be sent for Pneumocystis jirovecii immunofluorescence 
if Pneumocystis jirovecii pneumonia  is suspected in HIV-infected 
individuals.
The routine collection of blood cultures has not been shown to improve 
patient outcome in CAP and seldom results in a change of the initial 
empiric antibiotic.13 However, it is wise to obtain two sets of blood 
cultures prior to the administration of antibiotics in patients with severe 
CAP.14
Clinical judgement underlying co-morbidity and severity of CAP should 
guide the necessity and frequency of haematological and biochemical 
investigations. White cell count, serum urea and serum albumin are 
important in the further assessment of the severity of CAP. Renal 
function needs to be monitored if nephrotoxic drugs such as the 
aminoglycosides are used. HIV testing should be offered to all patients 
as a positive diagnosis may broaden the list of likely pathogens and 
influence antibiotic selection. The routine use of serum activity markers 
such as CRP and procalcitonin is not recommended. Serological tests 
for atypical organisms are not routinely indicated.
Oxygenation and the need for supplemental oxygen may be assessed 
with pulse oximetry, but arterial blood gas analysis is required to 
assess Pa CO2  in patients who are in respiratory distress and are tiring 
or where there is a concern of CO2 retention in patients with COPD. 
All patients with pleural effusion should undergo diagnostic 
thoracocentesis to rule out an empyema. In addition to the routine 
testing of pH, glucose, protein, LDH and MC&S, pleural fluid should 
also be sent for tuberculosis microscopy and culture.
Treatment of CAP
Numerous societies have developed guidelines for the management 
of CAP; the guidelines differ based on local conditions such as patient 
population, pattern of pathogen frequency and antibiotic resistance. 
Most guidelines divide patients with CAP into subgroups based on 
the need for hospitalisation, age, co-morbid disease and the severity 
of pneumonia. These subgroupings allow for recommendations on 
the most appropriate antibiotic choice, based on the frequency of 
likely pathogens in each group. Rational recommendations on the 
appropriate level of care can also be made.
 
It has been shown that implementation of CAP guidelines results in 
a significant decrease in morbidity and mortality.6 SATS has recently 
revised guidelines for the management of CAP in adults.15 Although 
these guidelines have not been validated, they are based on the 
latest evidence available from both local and international studies and 
on local antibiotic resistance profiles. Adherence to these guidelines 
should result in decreased mortality and prevent the ever-increasing 
antibiotic resistance problem in South Africa. Despite offering benefit to 
both the individual patient and the community, guidelines are seldom 
followed. Only 8% of the patients in a recent local study were treated 
according to the guidelines. Unfortunately the numbers in the study 
were too small to comment on the validity of the guidelines.2 The 
revised SATS guidelines algorithm is shown in Figure 1.
One of the most important aspects in the management of a patient with 
CAP is the decision of whether the patient can be safely treated as an 
outpatient or whether hospitalisation is required. Once a decision to 
hospitalise a patient is reached the appropriate level of care, ranging 
from a general ward to an intensive care unit, must be determined.
The need for hospitalisation is multi-factorial. Advanced age, 
preexisting conditions, complications of pneumonia, the need for 
supplemental oxygen and the ability to tolerate oral medication must 
be considered. In addition to the clinical assessment, psychosocial 
circumstances, such as the patient’s wishes, home support system, 
and factors such as substance abuse or homelessness need to 
be explored if outpatient therapy is being considered. If the patient 
is considered suitable for outpatient management after the above 
considerations have been taken into account, a prognostic score 
should be determined. Patients with a low predicted mortality are 
suitable for outpatient management.16
The SATS guidelines make use of the Modified British Thoracic Society 
Rule/CURB65 score. The CURB65 score is derived from five variables: 
Confusion, Urea > 7 mmol/l, Respiratory rate > 30 breaths per minute 
(bpm), low Blood pressure (systolic < 90 mm Hg, diastolic < 60 mm 
Hg) and age > 65 years. A point is given to each variable present and 
added up to reach a score between zero and five for the patient. The 
higher the score, the greater the predicted mortality.17
A CURB65 score of zero to one has a predicted mortality of 1.7% 
and these patients may be treated as outpatients.14 Patients with a 
CURB65 score of three or more have a high rate of mortality and 
would be suitable for ICU admission. The CURB65 score does not take 
co-morbid conditions into account and may underestimate the severity 
of CAP in patients with pre-existing disease. The CRB65 score does 
not require estimation of serum urea and is equivalent to the CURB65 
score for predicting mortality. It is useful for outpatient assessment.18
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Figure 1: Algorithm for the management of community-acquired pneumonia in adults
Reproduced with permission from S Afr Med J 2007;97 (12):1295-1306
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The overriding factor in the final decision of whether or not to admit 
a patient should remain the attending doctor’s clinical judgement. In 
cases where uncertainty exists one should err on the side of admission 
even if it is only for a short observation period.19 Patients who are 
treated as outpatients should be reassessed at 24–48 hours as this is 
the time period in which patients are most likely to deteriorate.19
 
If a patient is hospitalised the level of care is based on clinical 
judgement and guided by further assessment of severity, using clinical 
and laboratory parameters. Parameters suggesting severe infection 
are the following: 
§ Confusion or decreased level of consciousness
§ Respiratory rate > 30 bpm
§ Hypotension (systolic < 90 mm Hg or diastolic < 60 mm Hg)
§ Hypoxaemia (PaO2 < 7.5 KPa)
§ White cell count < 4 or > 30 ×109
§ Urea > 7 mm ol/l
The presence of two of these features suggests severe pneumonia 
that may require transfer to a high care facility. Three or more of these 
features suggest a need for management in an ICU.20 Again it is 
imperative that the attending doctor makes the final placement decision 
based on clinical judgement and common sense.
Early administration of appropriate antibiotics has been shown to 
decrease mortality in patients hospitalised for CAP.14 Investigations 
for an aetiological agent in CAP are time consuming and often 
inconclusive, thus therapy for CAP is empiric with antibiotic choice 
directed at the most likely organism for the patient and clinical scenario 
(see Figure 1). 
Resistance patterns of common pathogens and the therapeutic 
implications
S pneumoniae is the most common pathogen isolated in all the 
subgroups, thus any antibiotic chosen must have reliable anti-
pneumococcal cover.
β-lactams
The class of β-lactam antibiotics consists of the penicillins, 
aminopenicillins and cephalosporins. Pneumococcal resistance to 
this class of antibiotics is related to alterations of the penicillin binding 
chains (PBC) of the organism. This results in a decreased affinity of 
the antibiotic for the organism, which can be overcome with higher 
concentrations of β-lactam antibiotics.3 The pharmacokinetic and 
pharmacodynamic (PK/PD) indices of the β-lactams as well as their 
ability to reach high concentrations in the respiratory tract allow them 
to readily overcome in vitro reduced-penicillin-susceptible strains 
(penicillin-intermediate and -resistant strains) of pneumococci causing 
CAP. No difference in clinical outcome has been demonstrated 
between penicillin-susceptible and reduced-penicillin-susceptible 
strains when adequate doses of the penicillins have been used.21 
Clinical studies support the efficacy of the penicillin antibiotics in the 
treatment of reduced-penicillin-susceptible pneumococcal CAP.22 It is 
possible that as pneumococcus develops higher minimum inhibitory 
concentration (MIC) to penicillin, negative clinical outcomes may occur. 
Continued surveillance is essential to allow early detection of this 
potential problem.
 
The second-generation cephalosporin cefuroxime has borderline 
PK/PD indices,21 and clinically adverse outcomes have been observed 
when low doses (750 mg eight hourly IVI) are used, thus cefuroxime 
should only be given at a higher dosage for CAP (1 500 mg eight 
hourly).22 The third-generation cephalosporins continue to have good 
activity against reduced-penicillin-susceptible pneumococci.
H infuenzae may produce β-lactamase, which renders it resistant 
to the aminopenicillins; the addition of clavulanate, a β-lactamase 
inhibitor, overcomes this resistance. The overall rate (7%) of β-lactamase 
producing H influenzae is low in South Africa.23 However, patients with 
conditions that predispose them to infection with resistant H influenzae, 
such as COPD, should receive antibiotic treatment accordingly. 
β-lactams offer no cover against atypical organisms and an additional 
agent with atypical bacteria cover, usually a macro/azalide, should be 
added in cases where infection with an atypical organism is suspected. 
Taking all the current evidence into account the β-lactams are still the 
recommended first-line antibiotics for CAP of all severities.
Macrolides and azalides
South Africa’s rates of macro/azalide-resistant pneumococcus are 
amongst the highest in the world. A surveillance study of private 
laboratories conducted in 2000–2001 found 61% of pneumococcal 
isolates to be resistant to macro/azolides with 47% showing high-level 
resistance.23 This high-level macrolide resistance cannot be overcome 
with increased dosing and the macro/azalides should not be used as 
monotherapy in CAP.24 The major role for the macro/azalides is as 
add-on therapy for atypical bacteria cover and as part of combination 
therapy in the treatment of severe pneumonia.
Ketolides
Telithromycin has broad-spectrum antibacterial cover with activity 
against atypical pathogens and excellent activity against S pneumoniae 
including penicillin-resistant and erythromycin-resistant strains. It may 
not offer optimal activity against H influenzae.16 Its association with 
severe adverse events requires that it be used with caution.24 It is 
recommended that telithromycin be reserved for patients with severe 
allergy to β-lactams and cases of highly resistant pneumococcal CAP. 
Pneumococcal resistance to telithromycin is low.25
Respiratory fluoroquinolones
Levofloxacin, gemifloxacin and moxifloxacin have excellent activity 
against S pneumonia (including penicillin-resistant and erythromycin-
resistant strains) and the other common pathogens causing CAP, 
including the atypical bacteria. Pneumococcal resistance to and 
treatment failure of this class have been described and are on the rise 
with the increasing use of these agents.26 Exposure to fluoroquinolones 
in the previous three months increases the risk of resistance. The 
safety profile of the fluoroquinolones renders them unsuitable for 
routine use.24  As they are also effective second-line antituberculosis 
agents, patients with tuberculosis may show an initial clinical response 
if treated with fluoroquinolones. TB rapidly develops resistance when 
exposed to monotherapy, and these agents should be avoided if TB is 
suspected. 
Fluoroquinolones should be reserved for patients with severe penicillin 
allergy, failed first-line therapy, known infection with high-level 
penicillin-resistant pneumococci or who have received a β-lactam in 
the past three months. Combination therapy, usually a β-lactam and a 
macrolide, is superior to a fluoroquinolone alone in severe pneumonia. 
An additional agent should be added to the fluoroquinolones when 
treating severe CAP.27
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Aminoglycosides
Aminoglycosides are a poor choice for respiratory tract infections 
as they have limited penetration into the lung. In South Africa K 
pneumoniae is a common cause of severe CAP with a high mortality 
rate.28 The addition of an aminoglycoside to the initial therapy of 
severe CAP has been shown to significantly improve the mortality of 
patients with K pneumoniae,28 probably by controlling bacteraemia. 
As these patients cannot be separated clinically from patients with 
other causes of severe pneumonia, the addition of an aminoglycoside 
to the initial empiric therapy is recommended in patients with severe 
pneumonia. The aminoglycosides act synergistically with the β-lactams 
but not the fluoroquinolones. It is not known whether the addition of an 
aminoglycoside to a fluoroquinolone will confer the same benefit as 
demonstrated with the β-lactam-aminoglycoside combination. 
Doxycycline
The high prevalence of S pneumoniae resistance to doxycycline limits 
its use for CAP to add-on therapy to β-lactams for the cover of atypical 
organisms.
General principles of antibiotic therapy
An antibiotic should only be prescribed if a bacterial infection is 
suspected and not as prophylaxis against possible secondary bacterial 
infections. All antibiotics should be given in the correct dose at the 
correct interval. (See Table I.) If an antibiotic has been received in the 
preceding three months an antibiotic of a different class should be 
used. Combination therapy with a β-lactam and either a macrolide 
or a fluoroquinolone has been shown to offer a survival benefit over 
monotherapy in patients with severe CAP and hypotension.27 It is 
advised that combination therapy be used in patients with severe CAP.
Duration of therapy
The exact duration of therapy for CAP remains uncertain. The current 
guidelines recommend five to seven days therapy for CAP and 14 
days for severe Legionella infection.15 A recent trial has shown three-
day therapy to be safe and efficacious in patients admitted to hospital 
with mild to moderate CAP.29 Further trials are required to determine 
the optimal duration of therapy. At present, continuation of therapy for 
48–72 hours after vital signs normalise is a safe option. Patients on 
parenteral therapy may be converted to the same oral formulation once 
vital signs return to normality.
Response to therapy
Most patients with CAP should show an improvement and stabilisation 
of vital signs within 48–72 hours.30 Cough and dyspnoea usually 
resolve within 14 days but non-respiratory symptoms such as fatigue 
may persist for longer, particularly in patients with co-morbid disease 
and in the elderly.31 While patients should return to their pre-pneumonia 
condition within six months, evidence suggests a lower long-term 
survival rate in elderly patients who have had pneumonia than in 
matched controls who have not.31
Failure of response
Severe pneumonia, old age, co-morbid disease and 
immunosuppression may cause a delay in clinical stabilisation. Failure 
to show stabilisation at 72 hours in the absence of risk factors for a 
protracted course or deterioration in the patient’s clinical condition 
suggests treatment failure.30 Causes for treatment failure may be 
either infectious or non-infectious. Infectious causes to be considered 
are complications of pneumonia (empyema or cavitation), resistance 
of usual organisms and infection with organisms not covered by the 
recommended initial empirical therapy such as tuberculosis or P 
jirovecii or a superadded nosocomial infection.
Non-infectious causes to be considered are neoplasia, pulmonary 
embolism, pulmonary oedema and vasculitis with pulmonary 
haemorrhage. Treatment failure is usually due to an infectious 
agent,30 and all microbiological specimens should be reviewed and 
new specimens obtained. A change in antibiotics to cover resistant 
pneumococci, S aureus and Pseudomonas aeruginosa is required. 
Patients with treatment failure have a high mortality and should be 
referred to a specialist for further management. 
Adjuvant therapy
Supplemental oxygen should be administered when required. 
Attention must be paid to the patient’s state of hydration and nutritional 
requirements. Systemic corticosteroids have been shown to decrease 
both morbidity and mortality in patients with severe CAP and may be 
Penicillins Fluroquinolones
Oral
Amoxycillin: 1 g eight hourly
Amoxycillin-clavulanate: minimum 
of 500 mg amoxicillin with 125 mg 
clavulanate eight hourly. Sustained 
release preparations allow for 1 g 
12-hourly dosing.
Oral
Gemifloxacin: 320 mg daily
Levofloxacin: 500 mg 12 hourly or 
750 mg daily
Moxifloxacin: 400 mg daily
Parenteral
Penicillin G: 2-4 million units six 
hourly
Ampicillin or Amoxycillin: 1-2 g six 
hourly
Amoxycillin-clavulanate: 1,2 g eight 
hourly
Parenteral
Levofloxacin: 500 mg 12 hourly or 
750 mg daily




Cefuroxime axetil: 750 mg – 1 gm 
12 hourly
Cefpodoxime: 400 mg 12 hourly 
Parenteral
Second generation
Cefuroxime: 1,5 g eight hourly
Third generation
Ceftriaxone: 2 g daily (can increase 
to 2 g 12 hourly)
Cefotaxime: 3–4 g daily in two–four 
divided doses
Parenteral
Amikacin: 15 mg/kg/day (maximum 
1,5 g daily)
gentamicin: 5–7 mg/kg/day (usual 
320 mg daily)




Erythromycin: 500 mg six hourly
Clarithromycin: 500 mg 12 hourly
Clarithromycin XL: 1g daily
Azithromycin: 500 mg daily
Parenteral
Erythromycin: 4–5 mg/kg six hourly 
given into a large vein
Clarithromycin: 500 mg 12 hourly
Azithromycin: 500 mg daily
Oral
Doxycycline: 200 mg stat followed 
by 100 mg 12 hourly  
Ketolides
Oral
Telithromycin: 800 mg daily
Table I: Recommended dosages of antibiotics for CAP
CPD Article
SA Fam Pract 2008                  Vol 50 No 322
CPD Article
SA Fam Pract 2008                  Vol 50 No 323
of value in this subgroup of patients. Prophylaxis against deep vein 
thrombosis with unfractionated heparin is recommended for all non-
ambulant patients.
Prevention of CAP
Vaccination against pneumococcus decreases the incidence of 
invasive pneumococcal disease32 and results in a lower morbidity 
and mortality in patients who later develop CAP.33 Pneumococcal 
vaccine is recommended for all persons who meet the recommended 
vaccination criteria. Influenza vaccination in at-risk persons decreases 
the incidence and severity of CAP. All persons with an indication for 
the influenza vaccine should be encouraged to receive it annually. 
Smoking is a risk factor for CAP and the development of invasive 
pneumococcal disease. All smokers should be encouraged to stop 
smoking. 
Conclusion 
CAP remains a common and potentially fatal condition. CAP is usually 
caused by a few pathogens and evidence is available to predict the 
most likely causative pathogen depending on patient age, co-morbidity 
and severity of the pneumonia. The resistance mechanisms and 
patterns are also known for the pathogens causing CAP. This allows 
for a rational choice of antibiotics for patients with CAP. SATS has 
released its revised guidelines for the management of CAP in adults, 
which, if adhered to, should result in improved survival for patients as 
well as limiting inappropriate antibiotic use and preventing antibiotic 
resistance.  
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